DD283929A5 - Pharmazeutische praeparate und verfahren zu deren herstellung - Google Patents

Pharmazeutische praeparate und verfahren zu deren herstellung Download PDF

Info

Publication number: DD283929A5
Authority: DD; German Democratic Republic
Prior art keywords: parts; primycin; mass; weight; preparation
Prior art date: 1988-06-16

Application number

DD89329637A

Other languages

German (de)

English (en)

Inventor

Anna Z Szabo

Jozsef Gaal

Katalin Marmosi

Gyula Sebestyen

Gizella Miholics

Marta Kovacs

Original Assignee

��@��@��@��@��@��@��Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-06-16

Filing date

1989-06-15

Publication date

1990-10-31

1989-06-15 Application filed by ��@��@��@��@��@��@��Kk�� filed Critical ��@��@��@��@��@��@��Kk��

1990-10-31 Publication of DD283929A5 publication Critical patent/DD283929A5/de

Links

238000002360 preparation method Methods 0.000 title claims abstract description 35
238000000034 method Methods 0.000 title claims abstract description 11
239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 33
NYWSLZMTZNODJM-MCGDBQAWSA-N 2-[5-[(4e,20e)-35-butyl-19-[(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,33-tetramethyl-36-oxo-1-oxacyclohexatriaconta-4,20-dien-2-yl]-4-hydroxyhexyl]guanidine Chemical compound OC1CC(O)CC(O)CC(O)CC(O)CCCC\C(C)=C\C(C)C(C(C)C(O)CCCN=C(N)N)OC(=O)C(CCCC)C(O)C(C)CCC(O)CCCC(O)CCCC(O)\C(C)=C\C1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NYWSLZMTZNODJM-MCGDBQAWSA-N 0.000 claims abstract description 32
229950010664 primycin Drugs 0.000 claims abstract description 32
NYWSLZMTZNODJM-SDUQVVOESA-N primycin Natural products CCCC[C@H]1[C@H](O)[C@H](C)CC[C@@H](O)CCC[C@@H](O)CCC[C@@H](O)C(=C[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)C[C@H](O)C[C@@H](O)C[C@H](O)C[C@H](O)CCCCC(=C[C@@H](C)[C@@H](OC1=O)[C@H](C)[C@H](O)CCCNC(=N)N)C)C NYWSLZMTZNODJM-SDUQVVOESA-N 0.000 claims abstract description 32
239000004548 suspo-emulsion Substances 0.000 claims abstract description 25
239000000203 mixture Substances 0.000 claims abstract description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
230000000844 anti-bacterial effect Effects 0.000 claims abstract description 7
238000009472 formulation Methods 0.000 claims abstract description 7
239000013543 active substance Substances 0.000 claims abstract description 5
239000002537 cosmetic Substances 0.000 claims abstract description 4
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 4
239000012153 distilled water Substances 0.000 claims abstract 3
239000000725 suspension Substances 0.000 claims abstract 3
239000012467 final product Substances 0.000 claims abstract 2
239000000499 gel Substances 0.000 claims description 13
239000006260 foam Substances 0.000 claims description 11
239000000443 aerosol Substances 0.000 claims description 7
239000002736 nonionic surfactant Substances 0.000 claims description 5
239000002674 ointment Substances 0.000 claims description 4
-1 sorbitan fatty acid ester Chemical class 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical class CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 2
235000014113 dietary fatty acids Nutrition 0.000 claims description 2
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
150000002170 ethers Chemical class 0.000 claims description 2
239000000194 fatty acid Substances 0.000 claims description 2
229930195729 fatty acid Natural products 0.000 claims description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
239000002245 particle Substances 0.000 claims description 2
229920001223 polyethylene glycol Polymers 0.000 claims description 2
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
230000000845 anti-microbial effect Effects 0.000 claims 1
239000003085 diluting agent Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 abstract description 2
239000000945 filler Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1
210000000481 breast Anatomy 0.000 description 15
238000012360 testing method Methods 0.000 description 15
241001465754 Metazoa Species 0.000 description 13
208000004396 mastitis Diseases 0.000 description 11
238000011282 treatment Methods 0.000 description 10
230000002906 microbiologic effect Effects 0.000 description 7
241000191967 Staphylococcus aureus Species 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
230000035876 healing Effects 0.000 description 4
235000015097 nutrients Nutrition 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
241000194017 Streptococcus Species 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
241000194032 Enterococcus faecalis Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
HOWJQLVNDUGZBI-UHFFFAOYSA-N butane;propane Chemical compound CCC.CCCC HOWJQLVNDUGZBI-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
229960002385 streptomycin sulfate Drugs 0.000 description 2
208000037816 tissue injury Diseases 0.000 description 2
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
DXCXWVLIDGPHEA-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-[(4-ethylpiperazin-1-yl)methyl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CN1CCN(CC1)CC DXCXWVLIDGPHEA-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
URWAJWIAIPFPJE-UHFFFAOYSA-N Rickamicin Natural products O1CC(O)(C)C(NC)C(O)C1OC1C(O)C(OC2C(CC=C(CN)O2)N)C(N)CC1N URWAJWIAIPFPJE-UHFFFAOYSA-N 0.000 description 1
206010040880 Skin irritation Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000002009 allergenic effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
238000007664 blowing Methods 0.000 description 1
ZYFYTWZIMOACBS-UHFFFAOYSA-N butan-1-ol;ethanol;hydrate Chemical compound O.CCO.CCCCO ZYFYTWZIMOACBS-UHFFFAOYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
229960003722 doxycycline Drugs 0.000 description 1
XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000000762 glandular Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000001282 iso-butane Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
238000012009 microbiological test Methods 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
239000001272 nitrous oxide Substances 0.000 description 1
229960001180 norfloxacin Drugs 0.000 description 1
OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
229960001699 ofloxacin Drugs 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
URWAJWIAIPFPJE-YFMIWBNJSA-N sisomycin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N URWAJWIAIPFPJE-YFMIWBNJSA-N 0.000 description 1
230000036556 skin irritation Effects 0.000 description 1
231100000475 skin irritation Toxicity 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dispersion Chemistry (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Colloid Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Control Of El Displays (AREA)
Ultra Sonic Daignosis Equipment (AREA)

DD89329637A 1988-06-16 1989-06-15 Pharmazeutische praeparate und verfahren zu deren herstellung DD283929A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU883088A HU203476B (en)	1988-06-16	1988-06-16	Process for producing stabile, aquous suspoemulsion containing primicin and suspoemulsionic pharmaceutical composition containing them as active component

Publications (1)

Publication Number	Publication Date
DD283929A5 true DD283929A5 (de)	1990-10-31

Family

ID=10962490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD89329637A DD283929A5 (de)	1988-06-16	1989-06-15	Pharmazeutische praeparate und verfahren zu deren herstellung

Country Status (15)

Country	Link
EP (1)	EP0347225B1 (ja)
JP (1)	JPH0240326A (ja)
CN (1)	CN1039356A (ja)
AT (1)	ATE93383T1 (ja)
CS (1)	CS274697B2 (ja)
DD (1)	DD283929A5 (ja)
DE (1)	DE68908620T2 (ja)
DK (1)	DK295789A (ja)
ES (1)	ES2059756T3 (ja)
FI (1)	FI892963A7 (ja)
HU (1)	HU203476B (ja)
NO (1)	NO892495L (ja)
PL (1)	PL161845B1 (ja)
RU (1)	RU1837870C (ja)
YU (1)	YU122689A (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2673508B1 (fr) *	1991-03-06	1993-06-25	Rhone Poulenc Chimie	Suspo-emulsions phytosanitaires.
FR2753626B1 (fr) *	1996-09-20	1998-11-06	Centre International De Rech Dermatologiques Galderma Cird Galderma	Nouvelles compositions topiques sous forme d'emulsion fluide h/e a forte teneur en glycol pro-penetrant
DE19945522A1 (de) *	1999-09-23	2001-04-05	Hexal Ag	Pharmazeutisches, wirkstoffhaltiges Gel
CN107304160A (zh) *	2016-04-18	2017-10-31	中石化石油工程技术服务有限公司	一种生物质醇醚及其制备方法和钻井液
CN109134211B (zh) *	2017-06-19	2022-03-11	中石化石油工程技术服务有限公司	一种石蜡醚及其制备方法和钻井液
DE102019100066A1 (de) *	2019-01-03	2020-07-09	Psholix Ag	Autostereoskopisches Display mit Integral-Imaging ähnlichen optischen Elementen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2514873C2 (de) *	1975-04-05	1983-12-29	Merck Patent Gmbh, 6100 Darmstadt	Salbengrundlage
HU173708B (hu) *	1975-06-20	1979-07-28	Chinoin Gyogyszer Es Vegyeszet	Sposob poluchenija geterokolloidnogo 18-arabinozil-2-n-butil-3,7,11,15,19,21,23,27,25,37-dekagidroksi-4,16,32,34,36-pentametil-tetrakona-16,32-dien-35-0-lakton-40-guanidiniumsul'fata
GB2103085B (en) *	1981-01-21	1984-03-21	Chinoin Gyogyszer Es Vegyeszet	Antimicrobial compositions containing primycin and doxycycline and/or sisomycin or a derivative thereof
HU194493B (en) *	1985-11-27	1988-02-29	Chinoin Gyogyszer Es Vegyeszet	Process for preparing primycin-containing colloidal basic gel and compositions comprising the same

1988
- 1988-06-16 HU HU883088A patent/HU203476B/hu not_active IP Right Cessation
1989
- 1989-06-15 RU SU894614364A patent/RU1837870C/ru active
- 1989-06-15 AT AT89306075T patent/ATE93383T1/de not_active IP Right Cessation
- 1989-06-15 EP EP89306075A patent/EP0347225B1/en not_active Expired - Lifetime
- 1989-06-15 DD DD89329637A patent/DD283929A5/de not_active IP Right Cessation
- 1989-06-15 ES ES89306075T patent/ES2059756T3/es not_active Expired - Lifetime
- 1989-06-15 JP JP1153543A patent/JPH0240326A/ja active Pending
- 1989-06-15 YU YU01226/89A patent/YU122689A/xx unknown
- 1989-06-15 DE DE89306075T patent/DE68908620T2/de not_active Expired - Fee Related
- 1989-06-15 NO NO89892495A patent/NO892495L/no unknown
- 1989-06-15 DK DK295789A patent/DK295789A/da not_active Application Discontinuation
- 1989-06-16 CN CN89106285A patent/CN1039356A/zh active Pending
- 1989-06-16 CS CS366289A patent/CS274697B2/cs unknown
- 1989-06-16 PL PL89280071A patent/PL161845B1/pl unknown
- 1989-06-16 FI FI892963A patent/FI892963A7/fi not_active IP Right Cessation

Also Published As

Publication number	Publication date
HU203476B (en)	1991-08-28
EP0347225B1 (en)	1993-08-25
DK295789D0 (da)	1989-06-15
PL161845B1 (pl)	1993-08-31
NO892495D0 (no)	1989-06-15
CS366289A2 (en)	1991-04-11
ATE93383T1 (de)	1993-09-15
EP0347225A2 (en)	1989-12-20
DE68908620T2 (de)	1993-12-23
ES2059756T3 (es)	1994-11-16
FI892963L (fi)	1989-12-17
DK295789A (da)	1989-12-17
HUT51145A (en)	1990-04-28
JPH0240326A (ja)	1990-02-09
FI892963A7 (fi)	1989-12-17
DE68908620D1 (de)	1993-09-30
YU122689A (en)	1991-08-31
CS274697B2 (en)	1991-09-15
NO892495L (no)	1989-12-18
CN1039356A (zh)	1990-02-07
FI892963A0 (fi)	1989-06-16
RU1837870C (ru)	1993-08-30
EP0347225A3 (en)	1991-03-13

Legal Events

Date	Code	Title	Description
1996-07-18	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
US5217707A (en)	1993-06-08	Pharmaceutical composition and process for the preparation thereof
EP0060553B1 (de)	1985-12-27	Präparat zur Behandlung von Wunden der Hautoberfläche und Verfahren zur Herstellung des Präparats
DE69837348T2 (de)	2007-11-29	Verfahren zur inaktivierung von bakterien mit einbegriff von bakteriensporen
DE60105283T2 (de)	2005-09-01	Zusammensetzungen die molekulares iod enthalten
DE60028978T2 (de)	2007-02-22	Ophthalmische zusammensetzung enthaltend antibiotika und nsaids
DE68927669T2 (de)	1997-05-07	Verfahren zur herstellung von in lösungsmitteln verdünnbaren mikroträgern
DE102005045145B4 (de)	2025-09-25	Verwendung von Octenidindihydrochlorid in halbfesten Zubereitungen
DE69232338T2 (de)	2002-09-19	Benzopyranphenolderivate zur Anwendung als bakterienhemmende, antivirale und wundheilende Mittel
DE68916430T2 (de)	1994-10-13	Arzneimittelzubereitung zur behandlung von mastitis bei tier und mensch.
DE3784695T2 (de)	1993-10-14	Gebrauch von Gramineenextrakten als Arzneimittel.
DE1166412B (de)	1964-03-26	Medizinische Binden und Monatshygieneartikel
DE68917186T2 (de)	1995-01-05	Verwendung von Ofloxacin oder dessen Salzen zur Herstellung eines Lokalpräparats für die Behandlung von Otopathie.
DE2305998A1 (de)	1973-08-16	Neue desodorierende damenbinden auf der grundlage von perjodsaeure
DE1617780B2 (de)	1980-06-26	Vernarbungsmittel
DE3244321C2 (de)	1986-02-20	Zusammensetzung für die weibliche Intimhygiene
DD283929A5 (de)	1990-10-31	Pharmazeutische praeparate und verfahren zu deren herstellung
DE69333258T2 (de)	2004-08-26	Verwendung von lysozymdimer zur herstellung eines arzneimittels zur modulation der natürlichen abwehrvorgänge
DE69426385T2 (de)	2001-07-05	Präparate für die Wundheilung, die Iod und einen Zucker enthalten
EP0928192B1 (de)	2002-05-02	Antimykotisches gel mit hoher wirkstofffreisetzung
US5064815A (en)	1991-11-12	Primycin-containing colloidal basic gel
DE69801820T2 (de)	2002-04-11	Verwendung von Dichlorobenzyl Alkohol zur Herstellung einer Zusammenstellung zur topischen Behandlung von Entzündungen
DE3500755A1 (de)	1985-07-25	Polymeres material mit enzymatischer wirkung, verfahren zu seiner herstellung und seine verwendung als oder in einem arzneimittel
WO2000033829A1 (de)	2000-06-15	Verwendung von poly (hexamethylen) biguanid zur herstellung eines mittels zur förderung der heilung von infektionsfreien wunden
DE2623249A1 (de)	1976-12-09	Wasserfreie jodophore reinigungsloesung
DE4300969A1 (ja)	1993-07-22